The FDA-approved anti-PD-1 treatments and ongoing clinical studies for renal-cell carcinoma, HNSCC, NSCLC, and bladder cancer are outlined in Table 1. The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.